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a b s t r a c t
BACKGROUND: Pleomorphic xanthoastrocytoma (PXA) classiﬁed as a low Grade (WHO II) astrocytic neoplasm. It is known for its relatively favorable prognosis. It most commonly occurs in young adults.
Malignant progression in PXA has been frequently reported since its ﬁrst description in 1979; however, the presentation of a primary anaplastic PXA tumor with an aggressive clinical course in adults is
rare especially in the later age group.
CASE DESCRIPTION: We present a case of primary anaplastic PXA in a 53 year old male that manifested with
an early recurrence pattern at 9 weeks. Treatment performed was surgical excision and external beam
radiotherapy. The aforementioned tumor followed an aggressive clinical course. Tumor cells exhibited
the characteristic expression of GFAP (Glial ﬁbrillary acidic protein), higher proliferative index (8–10%) on
Ki-67 staining along with the presence of increased mitoses ( >5/10hpf). A review of previously reported
primary anaplastic pleomorphic xanthoastrocytoma cases in adults with histological features was also
done.
CONCLUSION: Our review of all reported cases of APXA in adults concludes that the clinical behavior of this
tumor varies considerably from its benign variant. Early disease recurrence in anaplastic pleomorphic
xanthoastrocytomas is associated with fatal outcomes. As per our review of literature it is seen that
anaplastic variant of PXA shows histological characteristics as well as clinical course comparable with
Grade III astrocytomas.
We recommend further evaluation of PXA with anaplastic features regarding their genetic characteristics to understand the origin as well as behavior of this tumor.
© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Pleomorphic xanthoastrocytoma (PXA) is an astrocytic neoplasm with a relatively favorable prognosis [8]. According to WHO
classiﬁcation for astrocytic neoplasms, it has been classiﬁed histologically as a grade II (benign) neoplasm [6]. The ﬁrst case
was reported in 1979 [11]. It is often superﬁcially located in the
cerebral cortex with leptomennigeal involvement. Morphologically it shows a pleomorphic histological appearance that includes
lipidized, GFAP-expressing tumor cells with cytoplasmic xanthic
change surrounded by a reticulin network [9]. It has been frequently
seen that tumors initially diagnosed as PXA have later shown malig-

nant progression to high grade astrocytomas (grade III or IV). In
these cases the initial histological ﬁndings corresponded to a grade
II neoplasm; however over the recurrences it was found to be malignant [3]. To the best of our knowledge, only a few cases have been
reported in the literature, which demonstrate a PXA tumor presenting with anaplastic features at initial presentation. These cases
have been reported mostly in children and young adults ranging
between 7–25 years [16]. Here we present a case of a primary
anaplastic PXA tumor in the later age group with an unusual early
recurrence pattern. We then review the literature of previously
reported cases of primary anaplastic PXA tumors in adults.
2. Case description
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E-mail addresses: uk choudry@hotmail.com (U.K. Choudry),
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55 years old male presented with a history of sudden onset
headaches and two episodes of generalized tonic clonic seizures in
3 months. Neurological examination did not show any focal motor
or sensory deﬁcits. MRI brain showed a 2.2 × 1.3 × 1.1 cm nodular

http://dx.doi.org/10.1016/j.ijscr.2016.08.022
2210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. (A) MRI Brain T1 weighted showing hypointense nodular thickening in the left temporal lobe and para sylvian ﬁssure. (B) T2 weighted image showing hyperintense
lesion in the left temporal lobe. (C) T1 contrast image showing patchy enhancement in the left temporal lobe.

Fig. 2. MR spectroscopy showing high Choline/Creatine and high Choline/NAA ratios in the enhancing areas and persistent lactate peak in all enhancing areas favoring
neoplastic lesion.

Fig. 3. MRI Brain showing signiﬁcant overall increase in the size of tumor involving the left frontal, temporal and parietal lobes with perilesional edema and post surgical
changes in T1, T1 post contrast and T2 weighted images respectively.
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Fig. 4. A. PXA tumor exhibiting numerous eosinophilic hyaline globule. B. Tumor showing sheets of astrocytic cells having pleomorphic nuclei with some cells having
xanthomatous cytoplasm. Presence of frequent mitoses (arrows showing two mitotic ﬁgure) 40×. C. Tumor showing sheets of spindly to large polygonal astrocytic cells
having pleomorphic nuclei with nuclear inclusions 40×. D. PXA exhibiting necrosis.

thickening and enhancement along left medial temporal lobe and
sylvian ﬁssure. It appeared as a multicystic lesion with peripheral
enhancement and marked perilesional oedema (Fig. 1). MR Spectroscopy showed high choline/creatine and high choline/NAA ratios
in the enhancing areas (Fig. 2). Patient underwent a left sided pterional craniotomy for excision of the lesion. Gross total resection
of the tumor was performed. Immediate post operative MRI scan
was not done due to ﬁnancial constraints. Biopsy report suggested
a neoplastic lesion composed of plump spindle-shaped pleomorphic cells having elongated nuclei with eosinophilic cytoplasm
and other cells having bizarre pleomorphic nuclei with abundant
cytoplasm. GFAP (glial ﬁbrillary acidic protein) immune staining
showed diffuse expression in tumor cells.Ki-67 staining showed
a proliferative index of upto 8–10% in some areas along with
the presence of increased mitoses (>5/10hpf). H & E staining also
showed a few xanthomatous cells along with areas of focal necrosis. CD34 immune staining was negative excluding epitheliod cell
glioblastoma (Figs. 4 and 5). Overall ﬁndings were suggestive of
an anaplastic pleomorphic xanthoastrocytoma. Case was discussed
in the tumor board meeting and external beam radiotherapy was
advised. On follow up visit patient exhibited mild to moderate cognitive impairment, sensory dysphasia and disorientation. MRI scan
was repeated 9 weeks after surgery. Repeat scan showed a signiﬁcant overall increase in tumor size with both multifocal cystic and
solid components involving left frontal, temporal and parietal lobes

measuring approximately 9.6 × 5.1 × 5 cm clearly elicited disease
progression (Fig. 3). The prognosis of the patient was discussed with
family regarding further management plan and it was decided to
continue radiotherapy and no surgical intervention was planned.
Patient died at 16 weeks from the time of initial diagnosis.

3. Discussion
PXA with anaplastic features is a rare tumor hence no deﬁnitive treatment guidelines have been established so far. The recent
consolidated review of literature by Tmara et al. [24] in 2012 has
reported 20 cases of primary anaplastic PXA in adults (18 above)
so far. We report a total of 24 cases of primary APXA in adults
from 1979 to 2016. We describe this case of primary anaplastic PXA in an adult male with special regard to a rapid disease
progression only after a 9 weeks interval. To the best of our knowledge only one case of primary anaplastic PXA has been reported
to have an earlier recurrence at 1 month (Kim et al., 2009) [12].
The average recurrence interval as per our literature review was
approximately 14 months from the time of initial diagnosis. The
APXA lesion was found to be mostly located in temporal and parietal lobes in most of the cases. It showed similar pattern involving
the medial temporal lobe and para sylvian ﬁssure in the aforementioned case description. Previous studies have shown presence
of neuroglial tumor markers like GFAP expression with reticulin
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Fig. 5. E. Immunohistochemistry showing diffuse GFAP staining. F. Negative CD34 staining. G. ki 67 staining showing diffuse proliferative index of 8–10% and presence of
increased mitosis (>5–10/hpf).

deposition as it was seen in this case [23]. Our inference about
behavior of PXA as an anaplastic tumor stems from the fact that
tumor showed proliferative index of 8–10% in some areas, which
along with the presence of increased mitoses (>5/10hpf) corresponded to WHO grade III classiﬁcation of diffuse astrocytomas
[15]. Previously reported cases of APXA also have shown similar
histological characteristics (Table 2). It was seen that presence of
pleomorphism was a consistent feature in majority of the cases.
The APXA tissue sections show bizarre giant cells that are multinucleated or have multilobulated nuclei, with intracytoplasmatic
lipid-containing vacuoles (xanthic), and are generally organized in
alveolar structures, with an abundant surrounding reticulin network and perivascular lymphoid inﬁltrates. In contrast to benign
PXA, the anaplastic variants have consistently shown high mitotic
activity along with areas of focal necrosis in most of the cases. Long
term control of anaplastic PXA with recurrences has been attributed
to postsurgical stereotactic radiation therapy (Koga, Tomoyuki, et
al) [13]. However due to its unavailability in our facility we planned
to provide external beam radiation therapy for long term palliative control of tumor. According to the current review of literature
the most commonly used treatment option was surgical excision
and post surgical radiotherapy. Complete surgical excision is still an
effective treatment in benign PXA with excellent 5 year and 10 year
survival rates; however, we found that gross total resection in APXA
is still associated with frequent recurrences. Previously there was
no sufﬁcient literature supporting the role of chemotherapy in the

treatment of pleomorphic xanthoastrocytomas in adults, recent
studies have shown the role of BRAF V600E inhibitors in treatment
of PXA tumors pertaining to the high frequency of these mutations
in PXA tumors [22]. Due to the lack of BRAFV600E testing in our
facility, no chemotherapy was planned for this patient. The average
survival in months among the reported APXA cases was approximately 24 months from the time of initial diagnosis according to
our case review (Table 1). This indicates a relatively poor prognosis
in patients with anaplastic PXA tumor at the initial presentation
when compared with the benign PXA tumors in adults [19].

4. Conclusion
Our review of all reported cases of APXA in adults concludes
that the clinical behavior of this tumor varies considerably from
its benign variant. As per this review of literature it is seen that
anaplastic variant of PXA shows histological characteristics as well
as clinical course comparable with Grade III astrocytomas. Early
disease recurrence in anaplastic pleomorphic xanthoastrocytomas
is associated with fatal outcomes.
We recommend further evaluation of PXA with anaplastic features regarding their genetic characteristics to understand the
origin as well as behavior of this tumor.
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Table 1
Review of previously reported primary anaplastic Pleomorphic xanthoastrocytoma cases in adults.
Author (Date)

Age/sex

Site

Treatment

Recurrence
Interval
(months)

Net survival
(months)

Goldring et al.
[7]
Iwaki et al. [9]

24/female

Temporal lobe

Surgery + chemotherapy

12 months

12 months

30/male

Surgery + radiotherapy

6 months

10 months

Perry et al. [21]

18/male

Parietooccipital
sulcus
Temporal lobe

Surgery + radiotherapy + chemotherapy

48 months

Tonn et al. [23]

18/male

Surgery + radiotherapy + chemotherapy

30 months

Chakrabarty
et al. [3]

49/male
40/male

Surgery + radiotherapy
Surgery + radiotherapy

Not reported
Not reported

Not reported
Not reported

Buccerio et al.
[2]
Zhuang et al.
[25]
Gelpi et al. [5]
Asano et al. [1]
Marton et al.
[16]
Hirose et al. [8]

65/male

Temporal + occipital
lobe
Temporal + occipital
lobe
Temporal lobe
Thalamic

Multiple
recurrences
8 months

Surgery + Radiotherapy

22 months

22 months

53/female

Frontal lobe

Surgery + radiotherapy + chemotherapy

Not reported

24 months

43/female
59/female
40/female

Occipital lobe
Temporal lobe
Temporal lobe

Surgery + Radiotherapy
Surgery
Surgery

36 months
Not reported
30 months

Alive
36 months
30 months

52/male
39/female
25/male

Surgery
Surgery + radiotherapy + chemotherapy
Surgery

Not reported
Not reported
Not reported

Alive
Not reported
Not reported

Kim et al. [12]
Koga et al. [13]
Frank et al. [4]
Lacoste-Collin
et al. [14]
Nern, Christian
et al. [18]
Kosuke, et al.
[10]
Montano el al.
[17]

45/male
47/female
28/male
45/female

Frontal lobe
Frontal + Temporal
lobe
Cerebellum
Temporal lobe
Frontal lobe
Temporal lobe
Peri ventricular

Surgery
Surgery + Radiotherapy
Surgery + radiotherapy + chemotherapy
Biopsy only

1 month
Not reported
14 months
Not reported

17 months
Not reported
Not reported
Not reported

57/male

Temporal lobe

Surgery + radiotherapy + chemotherapy

10 months

12 months

61/female

Pineal Gland

Surgery + radiotherapy + chemotherapy

Not reported

Alive

22/male

Surgery + radiotherapy + chemotherapy

Not reported

Alive

Usama et al.
(Present study)

53/male

Parietal
lobe + Temporal
lobe
Temporal
lobe + sylvian

Surgery + Radiotherapy

2 months

4 months

Table 2
Comparison of histological features of previously reported Anaplastic PXA tumors with the present study. (Mitosis; 0–2 cells/hpf = +; 3–5 cells/hpf = ++; 5–10 cells/hpf = ++ + ).
Author

Pleomorphism

Iwaki et al. [9]
Perry et al. [21]
Tonn et al. [23]
Buccerio et al. [2]
Asano et al. [1]
Marton et al. [16]
Hirose et al. [8]
Kim et al. [12]
Koga et al. [13]
Frank et al. [4]
Lacoste-Collin et al. [14]
Nern, Christian et al. [18]
Kosuke, et al. [10]
Usama et al. (Present study)

+
+
+
+
+
+
+
+
+
+
+
+
+
+

Conﬂicts of interest
None.
Funding

Eosinophilic hyaline globules

+
+

+

+

+
+
+
+

+

Nuclear inclusions

Xanthomatous cells

Mitosis

Spindle cells

+

+

+++
+++
+
+
+++
+++
+ + +
++
+
+
+++
++
+
+++

+

+
+
+
+

+

+
+
+
+
+
+

+

+
+

+
+

+

+

GFAP

+
+

+
+
+
+

Necrosis

+
+
+
+++

+
+

+
+

+

+
+
+
+
+
+

Consent
Written informed consent was obtained from the patient for
publication of this case report and accompanying images. A copy
of the written consent will be made available for review by the
Editor-in-Chief of this journal on request¨.

None.
Author contribution
Ethical approval
Not required.
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